[go: up one dir, main page]

TN2013000087A1 - Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) - Google Patents

Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Info

Publication number
TN2013000087A1
TN2013000087A1 TNP2013000087A TN2013000087A TN2013000087A1 TN 2013000087 A1 TN2013000087 A1 TN 2013000087A1 TN P2013000087 A TNP2013000087 A TN P2013000087A TN 2013000087 A TN2013000087 A TN 2013000087A TN 2013000087 A1 TN2013000087 A1 TN 2013000087A1
Authority
TN
Tunisia
Prior art keywords
release liner
transdermal therapeutic
crystallization
therapeutic systems
protective film
Prior art date
Application number
TNP2013000087A
Other languages
English (en)
Inventor
Stefan Bracht
Ildiko Terebesi
Thomas Langguth
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44653285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of TN2013000087A1 publication Critical patent/TN2013000087A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2013000087A 2010-09-06 2013-03-05 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner) TN2013000087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010040299A DE102010040299A1 (de) 2010-09-06 2010-09-06 Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
PCT/EP2011/065204 WO2012031985A1 (fr) 2010-09-06 2011-09-02 Systèmes thérapeutiques transdermiques à feuille de protection inhibant la cristallisation (release liner)

Publications (1)

Publication Number Publication Date
TN2013000087A1 true TN2013000087A1 (en) 2014-06-25

Family

ID=44653285

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000087A TN2013000087A1 (en) 2010-09-06 2013-03-05 Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)

Country Status (33)

Country Link
US (2) US8557279B2 (fr)
EP (1) EP2613771A1 (fr)
JP (2) JP6104800B2 (fr)
KR (1) KR20130114127A (fr)
CN (1) CN103079549B (fr)
AP (1) AP3586A (fr)
AR (1) AR082907A1 (fr)
AU (1) AU2011298892B2 (fr)
BR (1) BR112013005305A2 (fr)
CA (1) CA2810103C (fr)
CL (1) CL2013000636A1 (fr)
CO (1) CO6690753A2 (fr)
CR (1) CR20130098A (fr)
CU (1) CU24172B1 (fr)
DE (1) DE102010040299A1 (fr)
DO (1) DOP2013000053A (fr)
EA (1) EA032575B1 (fr)
EC (1) ECSP13012477A (fr)
GT (1) GT201300062A (fr)
IL (2) IL224980A (fr)
MA (1) MA34581B1 (fr)
MX (1) MX2013002602A (fr)
MY (1) MY162768A (fr)
NZ (1) NZ607630A (fr)
PE (2) PE20131138A1 (fr)
PH (1) PH12013500429A1 (fr)
SG (2) SG10201506927TA (fr)
TN (1) TN2013000087A1 (fr)
TW (1) TWI576245B (fr)
UA (1) UA110217C2 (fr)
UY (1) UY33590A (fr)
WO (1) WO2012031985A1 (fr)
ZA (1) ZA201301389B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630208B (zh) 2008-12-08 2018-07-21 歐陸斯迪公司 二氫羥戊甲嗎啡
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH674618A5 (fr) * 1987-04-02 1990-06-29 Ciba Geigy Ag
EP0370220B1 (fr) 1988-10-27 1996-01-10 Schering Aktiengesellschaft Composition de Gestoden à application transdermique
JPH06502419A (ja) 1990-10-29 1994-03-17 アルザ・コーポレーション 経皮避妊製剤、方法及びデバイス
US5512292A (en) 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210711A1 (de) 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
DE19629468A1 (de) * 1996-07-11 1998-01-15 Schering Ag Transdermale therapeutische Systeme
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
MXPA02005224A (es) 1999-11-24 2003-09-25 Agile Therapeutics Inc Sistema y procedimiento mejorado para la administracion transdermica de un anticonceptivo.
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
EP1216699A1 (fr) 2000-12-21 2002-06-26 Schering Aktiengesellschaft Système transdermique comprenant un progestatif très puissant
US20030165547A1 (en) * 2001-05-18 2003-09-04 Elisabeth Picard-Lesboueyries Cosmetic uses of 3beta-acetoxy-7-oxo-DHEA
DE10261696A1 (de) 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
SI1594483T1 (sl) * 2003-02-21 2006-12-31 Schering Ag UV-stabilni transdermalni terapevtski obliz
JP4965263B2 (ja) 2003-12-12 2012-07-04 バイエル ファーマ アクチエンゲゼルシャフト 浸透増強剤を必要としないホルモンの経皮送達
UA89766C2 (en) * 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
ES2596809T3 (es) * 2004-10-08 2017-01-12 Noven Pharmaceuticals, Inc. Dispositivo de administración transdérmica de fármacos que incluye un refuerzo oclusivo
DE102004062182B4 (de) 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
JP2012504609A (ja) * 2008-10-06 2012-02-23 マイラン・テクノロジーズ，インコーポレイテッド アモルファスロチゴチン経皮システム

Also Published As

Publication number Publication date
ECSP13012477A (es) 2013-04-30
US20120082714A1 (en) 2012-04-05
UA110217C2 (en) 2015-12-10
UY33590A (es) 2011-10-31
EA201390246A1 (ru) 2013-09-30
CR20130098A (es) 2013-05-15
GT201300062A (es) 2015-01-16
JP6104800B2 (ja) 2017-03-29
MY162768A (en) 2017-07-14
AR082907A1 (es) 2013-01-16
TWI576245B (zh) 2017-04-01
CU24172B1 (es) 2016-04-25
DOP2013000053A (es) 2013-07-15
MA34581B1 (fr) 2013-10-02
CA2810103A1 (fr) 2012-03-15
AU2011298892B2 (en) 2015-03-12
ZA201301389B (en) 2021-05-26
TW201217165A (en) 2012-05-01
CU20130031A7 (es) 2013-05-31
US9060955B2 (en) 2015-06-23
EP2613771A1 (fr) 2013-07-17
BR112013005305A2 (pt) 2016-08-16
PE20131138A1 (es) 2013-10-26
MX2013002602A (es) 2013-04-08
IL251124B (en) 2020-07-30
IL251124A0 (en) 2017-04-30
PE20180198A1 (es) 2018-01-26
AU2011298892A1 (en) 2013-03-28
CN103079549A (zh) 2013-05-01
PH12013500429A1 (en) 2019-10-07
NZ607630A (en) 2015-02-27
JP2016216500A (ja) 2016-12-22
CO6690753A2 (es) 2013-06-17
IL224980A (en) 2017-07-31
CN103079549B (zh) 2016-11-02
DE102010040299A1 (de) 2012-03-08
SG187941A1 (en) 2013-04-30
EA032575B1 (ru) 2019-06-28
CA2810103C (fr) 2019-06-18
AP3586A (en) 2016-02-10
AP2013006787A0 (en) 2013-04-30
US20140018751A1 (en) 2014-01-16
JP2013536828A (ja) 2013-09-26
KR20130114127A (ko) 2013-10-16
CL2013000636A1 (es) 2013-09-13
SG10201506927TA (en) 2015-10-29
US8557279B2 (en) 2013-10-15
WO2012031985A1 (fr) 2012-03-15

Similar Documents

Publication Publication Date Title
MX2022013590A (es) Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
WO2011157416A3 (fr) Administration transdermique de mémantine
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
DK3479863T3 (da) Sammensætninger, fremgangsmåder og artikler indeholdende farmaceutisk nitrogenoxid og regulerede leveringssystemer deraf til patienter
MX2014002215A (es) Sistema terapeutico transdermico para clorhidrato de acido 5-aminolevulinico.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
TN2015000135A1 (en) Modified release formulations for oprozomib
AR094289A1 (es) Sistemas de administracion transdermica de farmacos para levonorgestrel y etinil estradiol
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
BR112014017834A8 (pt) Sistema de distribuição de fármacos
TN2013000087A1 (en) Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
WO2012111996A3 (fr) Administration transdermique contenant de la galantamine ou ses sels
GEP201606567B (en) Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same
MX2014008693A (es) Administracion transdermica de hormonas.
WO2013054178A3 (fr) Compositions pharmaceutiques à libération prolongée
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral
UA54088U (ru) Способ лечения системной красной волчанки
TH154739A (th) ระบบบำบัดผ่านผิวหนังด้วยฟิล์มปกป้องซึ่งยับยั้งการตกผลึก(แผ่นรองกันเปื้อน)
UA66406U (ru) Способ лечения остеопенического синдрома у беременных с перинатальным инфицированием
ES2422657A1 (es) Composición farmacéutica sólida de cilostazol